Massimo Boni, A.O.U. Maggiore della Carità di Novara e Fiorenza Enrico, Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo, si confrontano sui nuovi scenari che vedono il farmacista ospedaliero sempre più "protagonista", anche in ambito oncologico.
La targeted therapy con inibitori di BRAF in combinazione con inibitori di MEK conferma la propria efficacia anche a lungo termine.
Una selezione dei principali articoli della letteratura nazionale e internazionale per l’aggiornamento in farmacia clinica e gestionale
Background: As live expectancy and cancer incidence growing, polypharmacy in oncology patients is also increasing, raising the risk of developing potential drug–drug interactions. Objective: To assess the prevalence of clinically relevant potential drug–drug interactions among cancer patients who receive parenteral treatment at our outpatient clinic. Method Retrospective observational study which included randomly selected patients who had received parenteral treatment from November 1st 2016
Objective: To develop and pilot test a model in which a community-based clinical pharmacist was incorporated as part of a Medicare Annual Wellness Visit (AWV) to make deprescribing recommendations targeted at potentially inappropriate medications (PIMs) in the elderly. Setting: One family medicine Patient-centered medical home (PCMH) clinic in Buffalo, NY. Practice description: Implementation and evaluation of a pilot program incorporating a pharmacist
Objectives: To develop a pharmacist patient care services intervention reporting checklist to be used in conjunction with existing primary reporting tools. The tool should enhance consistent reporting of pharmacist patient care interventions. Tool use in pharmacist-patient care intervention reporting may increase: (1) likelihood for inclusion in higher order analyses and (2) successful replication. Methods: Adhering to principles of the Equator Network,
Background: Oral chemotherapy agents are being prescribed more frequently in many cancer types. In-office dispensing of oral chemotherapy agents has demonstrated clinical benefits and also shown financial benefit to third-party payers. A previous publication estimated over $200,000 in cost savings annually from in-office dispensing solely from medications returned to stock for credit. However, pharmacists in the in-office setting perform many
Background: Treatments for multiple myeloma (MM) have been rapidly evolving. Newly developed treatment regimens are likely to be more effective but also cost more than conventional therapies. Objective: We conducted a systematic review to compare the cost effectiveness of different classes of MM treatment. Methods: We searched the PubMed, MEDLINE, Web of Science, and EMBASE databases for studies published during 1990–2018 comparing
Background: Collaboration between pharmacists, doctors, and nurses in outpatient treatment is beneficial; however, such services are limited in Japan due to the lack of a healthcare reimbursement fee for outpatient pharmacy services at outpatient clinic. Objective: We evaluated the impact of a service in which clinical pharmacists collaborated with an oncologist at an outpatient clinic in the treatment of adverse drug
Background: Recent years have witnessed the rapid evolution of therapies in chronic-phase chronic myeloid leukemia (CP-CML). To assess the efficacy and tolerability of all reported front-line treatments for patients with newly diagnosed CML, a multiple-treatments meta-analysis was performed, which accounted for both direct and indirect comparisons among those treatments. Methods: Primary outcomes were the percentage of patients achieving major molecular response
